Inocaine eye drops 0.4%, 5 ml

Local anesthesia in ophthalmology:

• measurement of intraocular pressure (tonometry);

• gonioscopy;

• diagnostic scraping of the conjunctiva;

• extraction of foreign bodies and sutures from the cornea and conjunctiva;

• short-term surgical interventions on the cornea and conjunctiva.

The drug is instilled into the conjunctival sac, 1 drop. Long-term anesthesia (up to 1 hour) is provided by 3-fold instillation with an interval of 4-5 minutes.

Eye drops 0.4% in the form of a transparent colorless solution.

1 ml

oxybuprocaine hydrochloride 4 mg

Excipients: benzalkonium chloride, boric acid, disodium edetate, sodium chloride, water d / i.

Hypersensitivity to the components of the drug.

pharmachologic effect

Local anesthetic that blocks nerve endings. When applied topically, it penetrates well into tissues. Compared with tetracaine and other local anesthetics, it has a less pronounced irritant effect on the conjunctiva and cornea. Superficial anesthesia of the conjunctiva and cornea after the use of eye drops occurs after 30 seconds and lasts for 15 minutes.

Pharmacokinetics

Inocaine easily penetrates into the corneal stroma after a single instillation into the conjunctival cavity. Over the next 15 minutes, a quantitative decrease in the stromal concentration of the drug is observed, which provides a 12-15 minute period of anesthesia with a single instillation.

Side effect

Possibly: short-term tingling sensation, burning and conjunctival hyperemia, allergic reactions. Rarely: keratitis.

Application during pregnancy and lactation

Clinical experience with the use of the drug during pregnancy and lactation is not enough. The use of Inocaine during pregnancy and during breastfeeding is possible only in cases where the expected benefit of therapy to the mother outweighs the potential risk to the fetus or infant.

special instructions

The drug is intended only for instillation into the conjunctival sac. Do not use for injection. Not intended for long-term therapy in the complex treatment of eye diseases. Prolonged, repeated and prolonged use (as with other local anesthetics) can lead to persistent corneal opacity. During anesthesia, it is necessary to protect the eye from irritating chemicals, foreign bodies and friction.

Use in pediatrics

There is no sufficient experience in the use of the drug in children. The use of Inocaine in children is possible only in cases where the expected benefit of therapy outweighs the risk of developing possible side effects.

Overdose

There are no data on drug overdose.

Drug interactions

The literature does not describe the negative or positive effects with the simultaneous introduction of oxybuprocaine and other traditionally used eye drops into the conjunctival sac. It is noted that oxybuprocaine can theoretically reduce the antibacterial activity of sulfonamides